Ex vivo Ikkβ ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis

Autor: Sylvie Marleau, Ozge Kizilay Mancini, Huy Ong, Dominique Shum-Tim, Liliane Ménard, Marc J. Servant, David N. Huynh, Ines Colmegna
Rok vydání: 2020
Předmět:
Male
endocrine system diseases
Physiology
T-Lymphocytes
Myocardial Infarction
Adipose tissue
IκB kinase
030204 cardiovascular system & hematology
Lymphocyte Activation
0302 clinical medicine
Cells
Cultured
Cellular Senescence
Secretome
0303 health sciences
Gene knockdown
Middle Aged
3. Good health
I-kappa B Kinase
Phenotype
Female
medicine.symptom
Signal transduction
Inflammation Mediators
Cardiology and Cardiovascular Medicine
Signal Transduction
Inflammation
Mesenchymal Stem Cell Transplantation
03 medical and health sciences
In vivo
Physiology (medical)
medicine
Animals
Humans
Protein Kinase Inhibitors
030304 developmental biology
Aged
Cell Proliferation
business.industry
Mesenchymal stem cell
nutritional and metabolic diseases
Mesenchymal Stem Cells
Original Articles
Atherosclerosis
Coculture Techniques
Mice
Inbred C57BL
Disease Models
Animal
Diabetes Mellitus
Type 2
Case-Control Studies
Cancer research
business
Ex vivo
Zdroj: Cardiovasc Res
ISSN: 1755-3245
Popis: Aims Diabetes is a conventional risk factor for atherosclerotic cardiovascular disease and myocardial infarction (MI) is the most common cause of death among these patients. Mesenchymal stromal cells (MSCs) in patients with type 2 diabetes mellitus (T2DM) and atherosclerosis have impaired ability to suppress activated T-cells (i.e. reduced immunopotency). This is mediated by an inflammatory shift in MSC-secreted soluble factors (i.e. pro-inflammatory secretome) and can contribute to the reduced therapeutic effects of autologous T2DM and atherosclerosis-MSC post-MI. The signalling pathways driving the altered secretome of atherosclerosis- and T2DM-MSC are unknown. Specifically, the effect of IκB kinase β (IKKβ) modulation, a key regulator of inflammatory responses, on the immunopotency of MSCs from T2DM patients with advanced atherosclerosis has not been studied. Methods and results MSCs were isolated from adipose tissue obtained from patients with (i) atherosclerosis and T2DM (atherosclerosis+T2DM MSCs, n = 17) and (ii) atherosclerosis without T2DM (atherosclerosis MSCs, n = 17). MSCs from atherosclerosis+T2DM individuals displayed an inflammatory senescent phenotype and constitutively expressed active forms of effectors of the canonical IKKβ nuclear factor-κB transcription factors inflammatory pathway. Importantly, this constitutive pro-inflammatory IKKβ signature resulted in an altered secretome and impaired in vitro immunopotency and in vivo healing capacity in an acute MI model. Notably, treatment with a selective IKKβ inhibitor or IKKβ knockdown (KD) (clustered regularly interspaced short palindromic repeats/Cas9-mediated IKKβ KD) in atherosclerosis+T2DM MSCs reduced the production of pro-inflammatory secretome, increased survival, and rescued their immunopotency both in vitro and in vivo. Conclusions Constitutively active IKKβ reduces the immunopotency of atherosclerosis+T2DM MSC by changing their secretome composition. Modulation of IKKβ in atherosclerosis+T2DM MSCs enhances their myocardial repair ability.
Databáze: OpenAIRE
Externí odkaz: